Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 09:00 ET | Source: Imunon, Inc.

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...
September 29, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
April 12, 2022 08:30 ET | Source: Celsion Corporation

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
October 15, 2021 09:00 ET | Source: Celsion CORP

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...